{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:59:54Z","timestamp":1794322794465,"version":"4.9.0"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR 219"],"award-info":[{"award-number":["TRR 219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR 219"],"award-info":[{"award-number":["TRR 219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Toronto Merit Award","id":[{"id":"https:\/\/ror.org\/03dbr7087","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart & Stroke\/Richard Lewar Centre of Excellence in Cardiovascular Research","id":[{"id":"https:\/\/ror.org\/00qbpyp73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Canadian Institutes of Health Research-Kidney Foundation of Canada Team Grant","id":[{"id":"https:\/\/ror.org\/019a0gk53","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Individuals with chronic kidney disease (CKD) exhibit an increased risk for the development of cardiovascular disease (CVD) with its manifestations coronary artery disease, stroke, heart failure, arrhythmias, and sudden cardiac death. The presence of both, CVD and CKD has a major impact on the prognosis of patients. This association likely reflects the involvement of several pathophysiological mechanisms, including shared risk factors (e.g. diabetes and hypertension), as well as other factors such as inflammation, anaemia, volume overload, and the presence of uraemic toxins. Identifying and characterizing CKD is crucial for appropriate CVD risk prediction. Mitigating CVD risk in patients with CKD mandates a multidisciplinary approach involving cardiologists, nephrologists, and other health care professionals. The present State-of-the-Art Review addresses the current understanding on the pathophysiological link between CVD and CKD, clinical implications and challenges in the treatment of these patients.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf167","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:00:47Z","timestamp":1741251647000},"page":"2148-2160","source":"Crossref","is-referenced-by-count":158,"title":["Cardiovascular disease in chronic kidney disease"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-5219","authenticated-orcid":false,"given":"Katharina","family":"Marx-Sch\u00fctt","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen , Pauwelsstra\u00dfe 30, Aachen D-52074, Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-2967","authenticated-orcid":false,"given":"Joachim","family":"Jankowski","sequence":"additional","affiliation":[{"name":"Institute for Molecular Cardiovascular Research, University Hospital, RWTH Aachen , Pauwelsstra\u00dfe 30, Aachen 52074 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-718X","authenticated-orcid":false,"given":"Kunihiro","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6481","authenticated-orcid":false,"given":"Massimo","family":"Nardone","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen , Pauwelsstra\u00dfe 30, Aachen D-52074, Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025061522530883200_ehaf167-B1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025061522530883200_ehaf167-B2","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/s0140-6736(08)60952-6","article-title":"All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan","volume":"371","author":"Wen","year":"2008","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B3","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/01.asn.0000070152.11927.4a","article-title":"Prevalence of kidney damage in Australian adults: the AusDiab kidney study","volume":"14","author":"Chadban","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B4","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1681\/asn.2005121273","article-title":"International comparison of the relationship of chronic kidney disease prevalence and ESRD risk","volume":"17","author":"Hallan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B5","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"2025061522530883200_ehaf167-B6","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/s0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025061522530883200_ehaf167-B9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2025061522530883200_ehaf167-B10","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1161\/circulationaha.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cardfail.2009.07.002","article-title":"Impaired kidney function and atrial fibrillation in elderly subjects","volume":"16","author":"Deo","year":"2010","journal-title":"J Card Fail"},{"key":"2025061522530883200_ehaf167-B12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/ki.2014.393","article-title":"Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy","volume":"87","author":"Liao","year":"2015","journal-title":"Kidney Int"},{"key":"2025061522530883200_ehaf167-B13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/asn.2020030301","article-title":"Two-week burden of arrhythmias across CKD severity in a large community-based cohort: the ARIC study","volume":"32","author":"Kim","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ahj.2016.07.004","article-title":"Kidney function and sudden cardiac death in the community: the Atherosclerosis Risk in Communities (ARIC) study","volume":"180","author":"Suzuki","year":"2016","journal-title":"Am Heart J"},{"key":"2025061522530883200_ehaf167-B15","doi-asserted-by":"publisher","first-page":"e0266046","DOI":"10.1371\/journal.pone.0266046","article-title":"Chronic kidney disease and atrial fibrillation: a dangerous combination","volume":"17","author":"Ocak","year":"2022","journal-title":"PLoS One"},{"key":"2025061522530883200_ehaf167-B16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B17","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B18","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025061522530883200_ehaf167-B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2025061522530883200_ehaf167-B20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/circulationaha.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/circulationaha.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/ndt\/gfw025","article-title":"Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?","volume":"31","author":"Brandenburg","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B24","doi-asserted-by":"publisher","first-page":"e9804","DOI":"10.1097\/MD.0000000000009804","article-title":"Risk factors for heart valve calcification in chronic kidney disease","volume":"97","author":"Rong","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025061522530883200_ehaf167-B25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025061522530883200_ehaf167-B26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B27","doi-asserted-by":"publisher","first-page":"E40-45","DOI":"10.1111\/chf.12030","article-title":"Uremic cardiomyopathy: an underdiagnosed disease","volume":"19","author":"Alhaj","year":"2013","journal-title":"Congest Heart Fail"},{"key":"2025061522530883200_ehaf167-B28","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment","volume":"5","author":"Di Lullo","year":"2015","journal-title":"Cardiorenal Med"},{"key":"2025061522530883200_ehaf167-B30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11906-017-0700-y","article-title":"The un-observed automated office blood pressure measurement technique used in the SPRINT study points to a standard target office systolic blood pressure &lt;140 mmHg","volume":"19","author":"Kjeldsen","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"2025061522530883200_ehaf167-B32","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025061522530883200_ehaf167-B35","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"The Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B36","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0140-6736(08)60104-x","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B38","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B39","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025061522530883200_ehaf167-B40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B41","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/m13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025061522530883200_ehaf167-B44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B48","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/circulationaha.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B49","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2025061522530883200_ehaf167-B50","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B51","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circulationaha.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B54","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium\u2013glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2025061522530883200_ehaf167-B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025061522530883200_ehaf167-B56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","article-title":"Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis","volume":"9","author":"Filippatos","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025061522530883200_ehaf167-B57","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B58","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B59","doi-asserted-by":"publisher","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025061522530883200_ehaf167-B60","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025061522530883200_ehaf167-B61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025061522530883200_ehaf167-B62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B63","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B64","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B65","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1093\/eurheartj\/ehm501","article-title":"Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease","volume":"28","author":"Hu","year":"2007","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B66","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B68","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B69","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025061522530883200_ehaf167-B70","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2025061522530883200_ehaf167-B71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2215\/cjn.0000000584","article-title":"The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials","volume":"20","author":"Mendon\u00e7a","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B72","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B73","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B74","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B75","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B76","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B77","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/s0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2025061522530883200_ehaf167-B78","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B79","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1681\/asn.0000000000000425","article-title":"Estimated effect of restarting renin-angiotensin system inhibitors after discontinuation on kidney outcomes and mortality","volume":"35","author":"Hattori","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B80","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B81","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2025061522530883200_ehaf167-B82","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/ndt\/gfz167","article-title":"The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease","volume":"35","author":"Molnar","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B83","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ndt\/gfz187","article-title":"Beta-blockers in heart failure patients with severe chronic kidney disease-time for a randomized controlled trial?","volume":"35","author":"Agarwal","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B84","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B86","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025061522530883200_ehaf167-B87","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025061522530883200_ehaf167-B88","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B89","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B90","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025061522530883200_ehaf167-B91","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B92","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B93","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2025061522530883200_ehaf167-B94","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2025061522530883200_ehaf167-B95","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025061522530883200_ehaf167-B96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.03.015","article-title":"A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients","volume":"123","author":"de Jong","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2025061522530883200_ehaf167-B97","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.2215\/cjn.02400311","article-title":"Warfarin in atrial fibrillation patients with moderate chronic kidney disease","volume":"6","author":"Hart","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B98","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ndt\/gfab197","article-title":"Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis","volume":"37","author":"Zamberg","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025061522530883200_ehaf167-B99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2025061522530883200_ehaf167-B100","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/asn.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025061522530883200_ehaf167-B101","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/circulationaha.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"2025061522530883200_ehaf167-B102","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/pace.14537","article-title":"Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end-stage renal disease patients","volume":"45","author":"Jamal","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025061522530883200_ehaf167-B103","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000525388","article-title":"Catheter ablation for atrial fibrillation in patients with chronic kidney disease and on dialysis: a meta-analysis and review","volume":"12","author":"Chung","year":"2022","journal-title":"Cardiorenal Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/23\/2148\/62886947\/ehaf167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/23\/2148\/62886947\/ehaf167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:53:12Z","timestamp":1750027992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/23\/2148\/8107983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":103,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf167","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,14]]},"published":{"date-parts":[[2025,4,8]]}}}